Palvella Therapeutics (PVLA)
157.24
+1.77 (1.14%)
Upcoming Events
Latest Headlines
Form 4 PALVELLA THERAPEUTICS, For: Aug 19 Filed by: Goin Kathleen
August 20, 2026 4:05 PM - SEC Filing
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
August 19, 2026 4:57 PM - SEC Filing
Form SCHEDULE 13G/A PALVELLA THERAPEUTICS, Filed by: First Light Asset Management, LLC
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A PALVELLA THERAPEUTICS, Filed by: BIOTECHNOLOGY VALUE FUND L P
August 14, 2026 4:28 PM - SEC Filing
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: PRUDENTIAL FINANCIAL INC
August 10, 2026 2:12 PM - SEC Filing
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026 7:30 AM - Globe NewsWire
Form S-8 PALVELLA THERAPEUTICS,
August 4, 2026 4:20 PM - SEC Filing
Form 10-Q PALVELLA THERAPEUTICS, For: Jun 30
August 4, 2026 7:52 AM - SEC Filing
Palvella Therapeutics (PVLA) Misses Q2 EPS by 36c
August 4, 2026 7:39 AM - StreetInsider
Form 8-K PALVELLA THERAPEUTICS, For: Aug 04
August 4, 2026 7:31 AM - SEC Filing
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: JENNISON ASSOCIATES LLC
August 3, 2026 10:48 AM - SEC Filing
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: BlackRock, Inc.
July 29, 2026 3:22 PM - SEC Filing
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026 7:30 AM - Globe NewsWire
Pullback creates buying opportunity in this biotech stock: Oppenheimer
July 23, 2026 5:00 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)
July 22, 2026 6:52 AM - StreetInsider
Form 4 PALVELLA THERAPEUTICS, For: Jul 15 Filed by: Goin Kathleen
July 17, 2026 4:05 PM - SEC Filing
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
July 15, 2026 4:20 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jul 14
July 14, 2026 4:49 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
July 1, 2026 4:06 PM - SEC Filing
Form 3 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
July 1, 2026 4:05 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jun 29
June 30, 2026 7:37 AM - SEC Filing
Palvella Therapeutics adds Matt Pauls to its board of directors
June 30, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
June 30, 2026 7:30 AM - Globe NewsWire
Palvella files first NDA module for rare lymphatic malformation drug
June 29, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
June 29, 2026 7:30 AM - Globe NewsWire
Canaccord Reiterates Buy Rating on Palvella Therapeutics (PVLA)
June 25, 2026 6:41 AM - StreetInsider
Form 4 PALVELLA THERAPEUTICS, For: Jun 17 Filed by: Goin Kathleen
June 22, 2026 5:06 PM - SEC Filing
FDA grants rolling review for Palvella's rapamycin NDA for rare condition
June 22, 2026 7:30 AM - StreetInsider
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026 7:30 AM - Globe NewsWire
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
June 17, 2026 5:12 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 12 Filed by: Korenberg Matthew E
June 16, 2026 4:07 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jun 10
June 16, 2026 8:31 AM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: KIRITSY CHRISTOPHER P
June 12, 2026 4:08 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: JENKINS GEORGE M
June 12, 2026 4:08 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: HERON ELAINE J
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Doux John
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Davis Todd C
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Wessel Tadd S.
June 12, 2026 4:06 PM - SEC Filing
ResVita Bio adds dermatologist John Doux to board of directors
June 9, 2026 8:43 AM - StreetInsider
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
June 9, 2026 8:43 AM - PR NewsWire
Full Article List
